Illustratively, the insulin secretion signaling pathway emerges as a central orchestrator of glucose and lipid metabolism, with alterations in this pathway bearing direct consequences for the initiation and progression of cardiometabolic diseases, including obesity, T2D, and dyslipidemia. This evidence concerns the gene INS and type 2 diabetes mellitus.